Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xenon Pharmaceuticals Inc (NQ: XENE ) 45.00 -0.74 (-1.62%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Xenon Pharmaceuticals Inc < Previous 1 2 3 4 5 6 Next > The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal October 06, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... Via Benzinga The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight August 08, 2021 Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... Via Benzinga Exposures Product Safety Xenon Pharmaceuticals Raises $300M Via Equity October 06, 2021 Xenon Pharmaceuticals Inc (NASDAQ: XENE) priced its underwritten public offering of 8.5 million shares and pre-funded warrants to purchase up to 1.7 million shares... Via Benzinga Is Xenon Pharmaceuticals a Good Stock to Buy Now? October 05, 2021 Despite the big run-up yesterday, there could be enough fuel to push this biotech stock even higher. Via The Motley Fool 44 Biggest Movers From Yesterday October 05, 2021 Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of... Via Benzinga Earnings Scheduled For May 11, 2021 May 11, 2021 Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... Via Benzinga The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout October 05, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... Via Benzinga Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher October 04, 2021 Toward the end of trading Monday, the Dow traded down 1.09% to 33,951.17 while the NASDAQ fell 2.28% to 14,234.17. The S&P also fell, dropping 1.49% to 4,292.00. The U.S. has... Via Benzinga Topics Stocks Exposures US Equities XENE Stock: The Huge FDA News Sending Xenon Pharmaceuticals to the Moon October 04, 2021 Here's why investors in clinical-stage biotech stock Xenon Pharmaceuticals are cheering today as XENE stock runs wild. Via InvestorPlace Exposures Product Safety Mid-Day Market Update: Nasdaq Down 2%; Xenon Pharmaceuticals Shares Jump October 04, 2021 Midway through trading Monday, the Dow traded down 1.02% to 33,976.93 while the NASDAQ fell 2.14% to 14,255.08. The S&P also fell, dropping 1.23% to 4,303.43. The U.S. has the... Via Benzinga Topics Stocks Exposures US Equities 30 Stocks Moving In Monday's Mid-Day Session October 04, 2021 Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... Via Benzinga Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint October 04, 2021 Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult... Via Benzinga Mid-Morning Market Update: Markets Mostly Lower; US Factory Orders Surpass Estimates October 04, 2021 Following the market opening Monday, the Dow traded down 0.01% to 34,326.18 while the NASDAQ fell 1.4% to 14,362.69. The S&P also fell, dropping 0.51% to 4,334.77. The U.S.... Via Benzinga Topics Stocks Exposures US Equities Why Xenon Pharmaceuticals Stock Is Soaring Today October 04, 2021 Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... Via Benzinga Why Xenon Pharmaceuticals Stock Is Screaming Higher Today October 04, 2021 A positive mid-stage trial is powering this biotech stock higher today. Via The Motley Fool Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed September 28, 2021 Benzinga Pro data, Xenon Pharmaceuticals (NASDAQ:XENE) reported Q2 sales of $2.22 million. Earnings fell to a loss of $22.50 million, resulting in a 40.1% decrease from last... Via Benzinga The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering August 11, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... Via Benzinga Exposures Product Safety Earnings Scheduled For August 11, 2021 August 11, 2021 Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is... Via Benzinga 18 Key Biopharma Catalysts To Keep An Eye On In Q3 July 10, 2021 Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the... Via Talk Markets 18 Key Biopharma Catalysts To Keep An Eye On In Q3 July 10, 2021 Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... Via Benzinga Return On Capital Employed Overview: Xenon Pharmaceuticals June 18, 2021 In Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $4.36 million. Earnings were up 24.27%, but Xenon Pharmaceuticals still reported an overall loss of $16.06 million. In... Via Benzinga Looking Into Xenon Pharmaceuticals's Return On Capital Employed June 04, 2021 During Q1, Xenon Pharmaceuticals's (NASDAQ:XENE) reported sales totaled $4.36 million. Despite a 24.27% in earnings, the company posted a loss of $16.06 million. In Q4, Xenon... Via Benzinga Xenon Pharmaceuticals's Earnings Outlook May 10, 2021 Xenon Pharmaceuticals (NASDAQ:XENE) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings... Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
